Key result
Drug-eluting stents markedly reduce in-stent restenosis, but rates of late restenosis are emerging as higher than initially suggested.
Discusses the evolving landscape of in-stent restenosis treatment, noting that late restenosis rates with drug-eluting stents may be higher than initially thought.
Percutaneous transluminal coronary angioplasty has become the most frequently used method for myocardial revascularization.1 The use of uncoated coronary-artery stents during percutaneous intervention has decreased the incidence of acute complications and improved the outcome of patients,2 but restenosis within the stent compromises the long-term results. As a consequence, the prevention and treatment of in-stent restenosis have become priorities in interventional cardiology.Drug-eluting stents, which markedly reduce in-stent restenosis,3 have relegated all other therapeutic approaches to the background. However, it is gradually emerging that rates of late restenosis after the use of drug-eluting stents are higher than initial experience suggested, particularly . . .
No takes yet. Share an insight, caveat, or question.
Edoardo Camenzind (2006) conducted an editorial in In-stent restenosis. Drug-eluting stents was evaluated. Drug-eluting stents markedly reduce in-stent restenosis, but rates of late restenosis are emerging as higher than initially suggested.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: